Pipobroman

CAS: 54-91-1

Ref. TM-T4570

Informação sobre produto

• Nome: Pipobroman
• Sinónimos: Vercyte, A-8103, Amedel, 1,1′-(1,4-Piperazinediyl)bis[3-bromo-1-propanone], 1,1′-(Piperazine-1,4-diyl)bis(3-bromopropan-1-one), 1,4-Bis(3-bromopropionyl)piperazine, 1,4-Di(3-bromopropionyl)piperazine, 1-Propanone, 1,1'-(1,4-piperazinediyl)bis[3-bromo-, 3-Bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one, A 1803, Amedel, N,N'-Bis(3-bromopropionyl)piperazine, Nsc-25154, Piperazine, 1,4-bis(3-bromopropionyl)-, Vercyte
• CAS: 54-91-1

Descrição

Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.

• Marca: Targetmol

Propriedades químicas

• Peso molecular: 356.05
• Fórmula: C₁₀H₁₆Br₂N₂O₂
• Pureza: 93.01%
• Cor/forma: Solid